Trial · NCT07172204
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204, Phase 2, Recruiting, First Affiliated Hospital of Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML. Trials, record NCT07172204. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07172204
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
- NCT number
- NCT07172204
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 25 participants, estimated
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Conditions
- Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
- Interventions
- Alternately treated with VA/low CHA regimen
- First posted
- 2025-09-15
- Last updated
- 2026-02-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Negative rate of minimal residual lesions (MRD) | At day28 of the second alternating (one alternating is VA plus low-CHA) | Proportion of patients achieving MRD-negative status (≤0.1% leukemic blasts by flow cytometry) after two cycles of alternating VA/CHA therapy |
| Secondary | composite complete remission, CRc | At day28 of the first alternating and the second alternating (one alternating is VA plus low-CHA) | Proportion achieving CR or CRi per ELN 2022 criteria at each cycle completion |
| Secondary | Overall response rate, ORR | At day28 of the first alternating and the second alternating (one alternating is VA plus low-CHA) | Proportion achieving PR or better (CR/CRh/CRi/MLFS/PR) per IWG criteria at each cycle completion |
| Secondary | Overall Survival, OS | Time from enrollment to death from any cause, whichever came first, assessed up to 24 months | Time from enrollment to death from any cause, whichever came first (censored at last follow-up for survivors) |
| Secondary | disease-free survival, DFS | From the date of first response until the date of relapse or death from any cause, whichever came first, assessed up to 24 months | Time from first response to relapse or death (censored at last disease assessment) |
| Secondary | MRD negative DFS, DFS-MRD | From the date of first MRD-negative status until the date of MRD-positive, relapse or death due to relapse, whichever came first, assessed up to 24months. | Time from first MRD-negative status to MRD-positive (confirmed by a second check within 2 weeks). |
| Secondary | Event-free survival, EFS | from enrollment until the date of treatment failure, relapse or death from any cause, whichever came first, assessed up to 24 months | Time from enrollment to treatment failure (not achieved PR after the first alternating, or not achieved CR after 2 alternatings, or continuous MRD positive after 4 alternatings), relapse, or death. （one alternating is VA plus low-CHA) |
| Secondary | Incidence of adverse events (AEs) | up to 3 years | Incidence of CTCAE v6.0-graded AEs from day 1 of treatment to study completion |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07172204
GET https://conductscience.org/api/trials/v1/NCT07172204/registered